AstraZeneca, the global biopharmaceutical leader, has announced a ₹166 crore investment to expand its Global Capability Centre in Bengaluru, Karnataka. This strategic move will create 400 new jobs, growing the total workforce at the site to nearly 1,300 employees. The expansion will bolster AstraZeneca’s AI-powered innovation across Research and Development (R&D), global business services, IT, and digital health
Supporting AI-Driven Healthcare Innovation
The new Bengaluru facility will focus on:
- Advanced clinical research and trial support
- AI-powered healthcare solutions and data analytics
- Improving clinical trial efficiency and patient outcomes
- Specialised support for global regulatory compliance and pharmacovigilance
“Our global hub in Bangalore is a strategic investment that will play a vital role in advancing AstraZeneca’s bold ambition to deliver 20 new medicines by 2030,” said Jackie Crockford, Vice President of Global Business Services at AstraZeneca.
Building on AstraZeneca’s India Presence
This marks AstraZeneca’s second major investment in India in the past year, following the expansion of its Global Innovation and Technology Centre (GITC) in Chennai. With the Bengaluru expansion, the company’s total workforce across India will approach 4,000 employees.
“This hub enhances our R&D capabilities by connecting us with India’s exceptional scientific and technological expertise. The expansion will accelerate the development of innovative medicines and help us deliver across R&D, ultimately benefiting patients around the world,” said Magnus Nord, Vice President of Global Patient Safety BioPharma at AstraZeneca.
“This hub enhances our R&D capabilities by connecting us with India’s exceptional scientific and technological expertise. The expansion will accelerate the development of innovative medicines and help us deliver across R&D, ultimately benefiting patients around the world,” said Magnus Nord, Vice President of Global Patient Safety BioPharma at AstraZeneca.
Boosting Karnataka’s Life Sciences Ecosystem
Karnataka Health & Family Welfare Minister Dinesh Gundu Rao welcomed the investment:
“AstraZeneca’s investment reaffirms India’s leadership in science, technology, and healthcare, and is a testament to Karnataka’s robust life sciences ecosystem. This expansion aligns perfectly with our vision to create high-value employment opportunities while fostering innovation in critical sectors, making Bengaluru a global hub for biotechnology and R&D.”
“AstraZeneca’s investment reaffirms India’s leadership in science, technology, and healthcare, and is a testament to Karnataka’s robust life sciences ecosystem. This expansion aligns perfectly with our vision to create high-value employment opportunities while fostering innovation in critical sectors, making Bengaluru a global hub for biotechnology and R&D.”
Commitment to Sustainability
The new AstraZeneca Bengaluru facility has been designed to achieve LEED Platinum certification —a benchmark for environmental sustainability. Features include:
- 75% green energy sourcing
- Full wastewater recycling
- IoT-enabled systems for optimised energy management
This sustainable design reinforces AstraZeneca’s global commitment to environmental responsibility and carbon footprint reduction.
Why This Matters
India is rapidly emerging as a global hub for life sciences, biotechnology, and digital health innovation . AstraZeneca’s significant investment not only strengthens its R&D capabilities but also:
- Creates high-value jobs for India’s scientific and tech talent
- Supports India’s digital health transformation
- Reinforces Bengaluru’s status as a top destination for biotech R&D
Conclusion
AstraZeneca’s ₹166 crore expansion in Bengaluru highlights the company’s long-term commitment to India’s healthcare ecosystem and its global strategy to deliver innovative, life-changing medicines powered by AI and advanced technology.
Visit Our News section and follow us on LinkedIn and Twitter
